Alain P. Algazi
A5072582710- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Head and Neck Cancer Studies
- Colorectal and Anal Carcinomas
- Microbial Inactivation Methods
- Toxin Mechanisms and Immunotoxins
- Lung Cancer Treatments and Mutations
- Salivary Gland Tumors Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Cancer Research and Treatments
- Brain Metastases and Treatment
- Transgenic Plants and Applications
- HER2/EGFR in Cancer Research
- Click Chemistry and Applications
- RNA Interference and Gene Delivery
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Synthesis and biological activity
- Neuroscience and Music Perception
- Hearing Loss and Rehabilitation
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Computational Drug Discovery Methods
University of California, San Francisco
2016-2025
UCSF Helen Diller Family Comprehensive Cancer Center
2015-2025
University of California San Francisco Medical Center
2015-2023
City College of San Francisco
2015-2022
Northern California Melanoma Center
2017-2021
Seoul National University Hospital
2017
National Taiwan University Hospital
2017
Rutgers, The State University of New Jersey
2017
Melanoma Institute Australia
2016
Macquarie University
2016
The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.
Resistance to therapy with BRAF kinase inhibitors is associated reactivation of the mitogen-activated protein (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial combined treatment dabrafenib, selective inhibitor, trametinib, MAPK (MEK) inhibitor.
Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies nivolumab combined ipilimumab melanoma have excluded untreated brain metastases. We evaluated the efficacy safety plus who had
<h3>Importance</h3> The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. <h3>Objective</h3> To characterize association of pembrolizumab tumor response overall survival among patients advanced melanoma. <h3>Design, Settings, Participants</h3> Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration follow-up was 21 months. study...
Abstract We explored the association between liver metastases, tumor CD8+ T-cell count, and response in patients with melanoma or lung cancer treated anti-PD-1 antibody, pembrolizumab. The discovery cohort was drawn from phase I Keynote 001 trial, whereas validation 002, 006, EAP trials non–small cell (NSCLC) 001. Liver metastasis associated reduced shortened progression-free survival [PFS; objective rate (ORR), 30.6%; median PFS, 5.1 months] compared without (ORR, 56.3%; 20.1 months) P ≤...
Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response specific inhibitors critical in order stratify and rationally select combinations the context an expanding array therapeutic options.We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts 20 each prior treatment correlated subsequent with tumor immune...
Immunomodulatory anticancer drugs, such as the anti-programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs their possible correlation with treatment response.To describe frequency spectrum of AEs linked pembrolizumab response.A single-institution, retrospective medical record review was conducted cancer who were treated from March 1, 2011, to May 28,...
Purpose To establish the safety profile and antitumor activity of anti-programmed death 1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) that expressed programmed death-ligand (PD-L1). Patients Methods KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort, phase Ib trial pembrolizumab PD-L1-positive advanced solid tumors. Key eligibility criteria for NPC cohort included unresectable disease, failure on prior...
Antibodies inhibiting the programmed death receptor 1 (PD-1) have demonstrated significant activity in treatment of advanced cutaneous melanoma. The efficacy and safety PD-1 blockade patients with uveal melanoma has not been well characterized.Fifty-eight stage IV received or ligand (PD-L1) antibodies between 2009 2015 at 9 academic centers. Patients who were evaluable for response eligible analysis. Imaging was performed every 12 weeks investigators' discretion. Safety clinical outcomes,...
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to recommendations 2016 update. Depending stage options now include biochemotherapy high-dose ipilimumab. Treatment disease intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted re-assessment data supporting older recommended resulting...
Purpose To report the overall survival (OS) and clinical characteristics of BRAF inhibitor–naive long-term responders survivors treated with dabrafenib plus trametinib in a phase I II study patients V600 mutation–positive metastatic melanoma. Methods 150 mg twice daily 2 (the 150/2 group) from non–randomly assigned (part B) randomly C) cohorts were analyzed for progression-free OS separately. Baseline factors on treatment associations durable responses OS. Results For groups (n = 78), at 1,...
Therapeutic antibodies against programmed cell death receptor 1 (PD-1) are considered front-line therapy in metastatic melanoma. The efficacy of PD-1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described.A multi-institutional, retrospective cohort analysis identified adults advanced melanoma who received treatment nivolumab or pembrolizumab as standard clinical practice through expanded access programs published...
BackgroundPatients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) progressing on platinum-based chemotherapy have poor prognoses limited therapeutic options. Programmed death-1 (PD-1) its ligand 1 (PD-L1) are frequently upregulated in HNSCC. The international, multi-institutional, single-arm, phase II HAWK study (NCT02207530) evaluated durvalumab monotherapy, an anti-PD-L1 monoclonal antibody, PD-L1-high patients platinum-refractory R/M HNSCC.Patients...
CD8
Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent inhibitors. This study assessed the safety efficacy of dabrafenib trametinib patients who had received prior inhibitor treatment.In this open-label phase I/II study, we evaluated pharmacology, safety, trametinib. Here, report treated combination after disease progression treatment administered before enrollment (part...
Objectives: Treatment options for patients with unresectable or metastatic salivary gland carcinoma (SGC) are limited. Safety and efficacy of pembrolizumab SGC expressing programmed death ligand 1 (PD-L1) were explored. Materials Methods: A cohort advanced, PD-L1-positive was enrolled in the nonrandomized, multicohort, phase Ib trial advanced solid tumors (KEYNOTE-028; NCT02054806). Key inclusion criteria included recurrent disease, failure prior systemic therapy, PD-L1 expression on ≥1%...